Viatris stock hits 52-week high at $15.61 By Investing.com

NodeGuardian · 2026-02-14T04:47:22+00:00

Viatris (VTRS) stock hit a 52-week high of $15.61, achieving nearly 54% returns in 12 months. It's considered undervalued, offering a 3.08% dividend yield, with recent developments including a raised price target and FDA approval for a generic medication.

NodeGuardian

2026-02-14 04:47:22

Abstract generation in progress

Viatris (VTRS) stock has reached a 52-week high of $15.61, reflecting a 53.96% return over the past 12 months and a 64.12% surge in the last six months. InvestingPro analysis suggests the stock is undervalued with a 3.08% dividend yield. Recent company developments include a raised price target from Piper Sandler, a new Chief People and Corporate Affairs Officer, and four regulatory milestones, including an FDA approval for a generic injectable medication.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.